EP Patent

EP3795121A1 — Ureteral stent drug delivery device

Assigned to Taris Biomedical LLC · Expires 2021-03-24 · 5y expired

What this patent protects

Ureteral stent devices having improved drug delivery capabilities are provided. The ureteral stent device includes a ureteral stent comprising two opposed ends, and a drug delivery component associated with at least one end of the ureteral stent. The drug delivery component inclu…

USPTO Abstract

Ureteral stent devices having improved drug delivery capabilities are provided. The ureteral stent device includes a ureteral stent comprising two opposed ends, and a drug delivery component associated with at least one end of the ureteral stent. The drug delivery component includes a drug housing defining a drug reservoir containing a drug, wherein the drug housing is configured to release the drug in-vivo.

Drugs covered by this patent

Patent Metadata

Patent number
EP3795121A1
Jurisdiction
EP
Classification
—
Expires
2021-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Taris Biomedical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.